Already funded by the Macy Easom Cancer Research Foundation
The Macy Easom Research Foundation and cc-TDI have been longstanding partners with a series of milestones: creating resources (cell line characterizations) and international collaborations, developing innovative and efficient drug testing programs for hepatoblastoma, identifying drug candidates and further defining hepatoblastoma biology and novel potential drug targets. In the current project, we further characterize hepatoblastoma cell surface proteins CD24 and LRP1 as potential targets of an antibody-drug conjugate (ADC) drug. These studies are led by the Macy Easom Engineering Fellow, Samuel Rasmussen.